-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga·05/05/2026 12:45:27
Listen to the news
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.